A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis

CONCLUSION: Based on our findings, Ocrelizumab is the most efficient monoclonal antibody for primary PMS, although it is associated with a higher risk of infection. While other monoclonal antibodies did not show significant promise in treating PMS, more research is necessary.PMID:37209514 | DOI:10.1016/j.intimp.2023.110266
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Source Type: research